- Home
- CON vs VCEL Comparison
CON vs VCEL Comparison
Compare CON & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CON
- VCEL
- Stock Information
- Founded
- CON 1979
- VCEL 1989
- Country
- CON United States
- VCEL United States
- Employees
- CON N/A
- VCEL N/A
- Industry
- CON
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CON
- VCEL Health Care
- Exchange
- CON NYSE
- VCEL Nasdaq
- Market Cap
- CON 2.6B
- VCEL 2.1B
- IPO Year
- CON 2024
- VCEL 1997
- Fundamental
- Price
- CON $20.21
- VCEL $39.86
- Analyst Decision
- CON Strong Buy
- VCEL Strong Buy
- Analyst Count
- CON 7
- VCEL 8
- Target Price
- CON $29.00
- VCEL $62.00
- AVG Volume (30 Days)
- CON 770.7K
- VCEL 506.5K
- Earning Date
- CON 08-07-2025
- VCEL 07-31-2025
- Dividend Yield
- CON 1.23%
- VCEL N/A
- EPS Growth
- CON N/A
- VCEL 521.85
- EPS
- CON 1.30
- VCEL 0.05
- Revenue
- CON $1,933,346,000.00
- VCEL $238,541,000.00
- Revenue This Year
- CON $13.25
- VCEL $23.03
- Revenue Next Year
- CON $7.48
- VCEL $24.52
- P/E Ratio
- CON $15.58
- VCEL $767.69
- Revenue Growth
- CON 4.54
- VCEL 14.80
- 52 Week Low
- CON $18.89
- VCEL $34.87
- 52 Week High
- CON $24.81
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- CON N/A
- VCEL 49.87
- Support Level
- CON N/A
- VCEL $34.87
- Resistance Level
- CON N/A
- VCEL $41.00
- Average True Range (ATR)
- CON 0.00
- VCEL 1.77
- MACD
- CON 0.00
- VCEL 0.37
- Stochastic Oscillator
- CON 0.00
- VCEL 64.47
About CON CONCENTRA GROUP HOLDINGS PARENT INC
Concentra Group Holdings Parent Inc is a provider of occupational health services in the United States. The business is organized into three operating segments: occupational health centers, onsite health clinics, and other businesses.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.